IQVIA Holdings Inc.

What does IQVIA own?
The company owns its clinical research operations, healthcare data and analytics platforms, the IQVIA Connected Intelligence platform, and commercial services businesses.

Is IQVIA publicly traded?
Yes. It trades on the New York Stock Exchange under ticker IQV and is an S&P 500 component.

When was IQVIA founded?
The company formed in 2016 through the merger of Quintiles (founded 1982) and IMS Health (founded 1954).

What does IQVIA do?
It runs outsourced clinical trials for pharmaceutical companies as the world's largest contract research organization, and provides healthcare data, analytics, and commercial services to life sciences and healthcare clients.

Who owns IQVIA?
Public shareholders own the company through the NYSE listing, with institutional investors dominant.

What is the difference between R&DS and TAS?
R&DS is the clinical trials business; TAS is the data, analytics, and technology business. Together they cover the drug development and commercialization lifecycle.

IQVIA was formed in 2016 by the merger of two healthcare data giants with different origins. Quintiles, founded by Dennis Gillings in 1982 in Chapel Hill, North Carolina, essentially invented the contract research organization industry, growing from a small statistical services firm into the largest CRO in the world running clinical trials for pharmaceutical companies.

IMS Health, founded in 1954, built the dominant business of tracking pharmaceutical sales and prescribing data, becoming the information backbone of the drug industry's commercial operations. The 2016 merger combined the trials side with the data side under one roof, creating what the combined company later renamed IQVIA in 2017.

The post-merger era added technology acquisitions and the IQVIA Connected Intelligence platform, plus Healthcare-grade AI branding for its analytics offerings. Through 2025 the company navigated a biotech funding downturn that slowed clinical bookings, then recovered as funding conditions improved late in the year.

As a services and data company, IQVIA's footprint is primarily offices and people. Its reporting covers workforce practices, emissions from operations, and data ethics.

The material ethical dimension is health data privacy: the company's business depends on handling billions of patient records, and it positions privacy, de-identification, and regulatory compliance as core to its model under frameworks including HIPAA and GDPR.

No consumer certifications apply. Clinical trial conduct and research ethics are overseen through institutional review board processes and industry standards rather than company-specific certifications.

Health data privacy: The scale of IQVIA's patient data holdings draws periodic scrutiny over data provenance, de-identification practices, and the commercial use of health information, an industry-wide debate in which IQVIA is the largest player.

Clinical trial oversight: As the largest CRO, its trial conduct is subject to FDA, EMA, and global GCP inspections and periodic findings resolved through corrective actions, routine for the industry.

Competition concerns: Its data-market position has drawn periodic antitrust questions about health data concentration, though no major enforcement action exists on its record.